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Increased consumption of high-caloric carbohydrates contrib-
utes substantially to endemic non-alcoholic fatty liver disease
in humans, covering a histological spectrum from fatty liver
to steatohepatitis. Hypercaloric intake and lipogenetic effects
of fructose and endotoxin-driven activation of liver macro-
phages are suggested to be essential to disease progression. In
the present study, we show that a low dose of an anti-CD163-
IgG-dexamethasone conjugate targeting the hemoglobin
scavenger receptor CD163 in Kupffer cells and other M2-type
macrophages has a profound effect on liver inﬂammatory
changes in rats on a high-fructose diet. The diet induced severe
non-alcoholic steatohepatitis (NASH)-like changes within a few
weeks but the antibody-drug conjugate strongly reduced
inﬂammation, hepatocyte ballooning, ﬁbrosis, and glycogen
deposition. Non-conjugated dexamethasone or dexamethasone
conjugated to a control IgG did not have this effect but instead
exacerbated liver lipid accumulation. The low-dose anti-
CD163-IgG-dexamethasone conjugate displayed no apparent
systemic side effects. In conclusion, macrophage targeting by
antibody-directed anti-inﬂammatory low-dose glucocorticoid
therapy seems to be a promising approach for safe treatment
of fructose-induced liver inﬂammation.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the most common
chronic liver disease1 and its incidence has increased globally.2–4
NAFLD and its more progressed form, non-alcoholic steatohepatitis
(NASH) with inﬂammation and ﬁbrosis of the liver,5–7 can
be induced experimentally in rodents by high-fat and/or high-
carbohydrate feeding.8–10 A multi-hit hypothesis is widely
accepted as the pathogenic model of disease progression, in which
primary hits (i.e., insulin resistance and intrahepatic fat accumula-
tion) promote development of steatosis, sensitizing the liver to sec-
ondary hits (e.g., endotoxin exposure, pro-inﬂammatory cytokine
imbalance, and oxidative stress).11,12 Studies of animal models of
NAFLD/NASH have shown that liver macrophage (Kupffer cell) ac-
tivity has an important triggering role in development of the
disease.13,14
Special attention is given to dietary fructose, partly because the prev-
alence of NAFLD in humans has increased in parallel with the con-
sumption of fructose. Furthermore, fructose is far more effective in
inducing experimental NAFLD than glucose.8 The pathogenic mech-
anisms leading to fructose-induced NAFLD are not fully understood,
but it seems evident that the different metabolism and metabolic ef-
fects of fructose compared to glucose add to the general effects of hy-
percaloric intake.15,16 In brief, fructose in large quantities is almost
entirely metabolized in the liver, where it in an insulin-independent
way is converted into fructose-1-phosphate and triose-phosphates.
The essential fructokinase and aldolase B enzymes involved are not
regulated by hepatocyte energy status. Consequently, virtually all in-
gested fructose is metabolized to triose-phosphates in the liver, where
these intermediates are oxidized and converted to glucose, lactate, or
triglyceride (TG). TG formation by hepatic de novo lipogenesis con-
tributes to increased hepatic lipid accumulation and plasma TG levels.
To date, the gold standard for treatment of NAFLD consists of a life-
style modiﬁcation program aimed to achieve gradual weight loss
through dietary changes and physical exercise. However, medical
intervention to reverse the condition is desirable for individuals
with progressed inﬂammatory disease.4
Therapeutic agents with antioxidant effects such as vitamin E and
insulin-sensitizing substances such as thioglitazones, metformin,
glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dipep-
tidyl peptidase-4 inhibitors have been evaluated for treatment of
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NASH.17–19 The latter two classes of pharmacotherapies,20,21 collec-
tively designated incretin-based therapies, seem most promising,
but to date no efﬁcient drugs have been approved for NASH.22,23 Glu-
cocorticoids (GCs) may dampen progression of inﬂammation but
they are contraindicated because of their profound and well-known
side effects that may even induce NAFLD/NASH in liver hepato-
cytes.24 Low-dose GCs are a medical treatment option for acute
alcohol-induced steatohepatitis, although their marginal effect is a
matter of discussion.25,26
We therefore decided to investigate whether molecular targeting of
macrophages (and thereby bypassing hepatocytes) with a low-dose
GC may deliver GC at therapeutic doses to Kupffer cells and thereby
dampen fructose-induced steatohepatitis progression without adverse
GC effects. For this study, we used a recently developed anti-inﬂam-
matory antibody-drug conjugate (ADC) (Figure S1) composed of the
synthetic GC dexamethasone (dexa)27,28 linked to an antibody against
the macrophage receptor CD163. This drug conjugate exhibits
a strong dose-dependent reducing effect on endotoxin-induced
cytokine release in rats and pigs.27,29 Compared to free dexametha-
sone, potency of the CD163-targeted dexamethasone is 50-fold
stronger.27,29 CD163, which functions as the scavenger receptor30 of
haptoglobin-hemoglobin complexes31,32 and other ligands,28,33 is
highly upregulated in M2-type macrophages, including liver Kupffer
cells (main macrophage subset), and in inﬁltrating macrophages in
sites of inﬂammation.28,34 CD163 is a constitutive recycling endocytic
receptor for transport of cargo to lysosomes rather than a receptor for
intracellular signal transmission.28 This function, combined with its
Figure 1. Steatosis, Infiltration of Inflammatory
Cells, and Hepatocyte Ballooning in Rats on the
HFr Diet
Histological changes examined by H&E staining (10) of
rat liver after (A) 2 weeks on the STD diet, (B) 2 weeks on
the HFr diet, (C) 5 weeks on the HFr diet, or (D) 12 weeks
on the HFr diet. Scale bars represent 400 mm. Insets of
higher magnification 40 are shown in the lower right
corner. Arrowheads indicate areas of steatosis (S),
leukocyte infiltration (I), hepatocyte ballooning (B), and
fibrosis (F).
selected and high expression in macrophages,
makes it an ideal macrophage target for drug
delivery.
RESULTS
Development of NAFLD/NASH in Rats Fed a
High-Fructose Diet
Two weeks after initiation of a high-fructose
(HFr) diet, the livers of Sprague-Dawley rats ex-
hibited morphological signs of steatosis with fat
accumulation in hepatocytes (Figure 1B). The
steatosis at this stage was predominantly seen
as microvesicular fat inﬁltration with a compo-
nent of macrovesicular steatosis displacing the central hepatocyte nu-
cleus. After 5 weeks, hepatocyte ballooning was observed as a
morphological feature of early steatohepatitis (Figure 1C). Increased
hepatocyte ballooning, along with other histological lesions such as
Mallory bodies and glycogenated nuclei, appeared after 12 weeks in
rats fed an HFr diet (Figure 1D; Table 1). Inﬂammatory inﬁltrates
with leukocytes were initially observed after 2 weeks and they mark-
edly increased over time (Figures 1B–1D). The development of liver
ﬁbrosis was evident after 5 weeks (Figure 1C). Fibrosis was character-
ized by both pericellular and perivenular deposition, and advanced
ﬁbrosis with a distinct chicken-wire bridging pattern was seen after
12 weeks (Figure 1D). Immunostaining of macrophages revealed
that the population of CD163-positive cells (Figures 2A and 2B)
was also increased after 2 weeks (p = 0.0019), thus showing that the
Kupffer cell population is supplemented with inﬁltrating M2-type
macrophages.
Liver/body weight ratios were highly elevated after 12 weeks in rats on
the HFr diet compared to a standard (STD) diet (Table 1). Body
weight differences between the two groups were not seen until after
6 weeks on the HFr diet; however, from 6 to 12 weeks, the body weight
of rats on the HFr diet was signiﬁcantly higher compared to rats on
the STD diet (p = 0.026). After 2 weeks, serum levels of glucose as
well as aspartate transaminase (AST) activity were higher in rats on
the HFr diet compared to control rats on the STD diet. The serum
concentration of glucose, cholesterol, and triglyceride increased
over time (Table 1). Furthermore, the level of serum tumor necrosis
factor alpha (TNF-a) was elevated after 2 and 12 weeks; after
www.moleculartherapy.org
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12 weeks, both the levels of TNF-a and interleukin (IL)-1b were
signiﬁcantly higher in rats on the HFr diet compared to rats on the
STD diet (Table 1). In accordance with these fructose-induced
NASH-like effects, hepatic mRNA proﬁling of rats after 12 weeks
on the HFr diet revealed marked changes in the transcription level
of multiple genes involved in metabolism of carbohydrates, fatty
acids, and cholesterol as well as genes involved in adipokine and in-
sulin signaling (Table S1).
In conclusion, initial stages of steatosis and inﬂammation were
seen after 2 weeks and pronounced disease progression with
ﬁbrosis developed during the 12-week study period (Table 1).
These histopathological changes were accompanied by fructose-
induced production of pro-inﬂammatory cytokines as well as a
changed regulation of several metabolic pathways involved in
the development of NASH.35–38 This included upregulation of
genes critical for synthesis, activation, and oxidation of fatty
acids and downregulation of genes that contribute to intra- and
extracellular cholesterol homeostasis39–41 as well as insulin resis-
tance and signaling, respectively.42,43 The treatment effect of
targeting Kupffer cells with anti-CD163-dexamethasone was subse-
quently investigated in rats that developed HFr-diet-induced liver
disease.
Targeting of the Anti-CD163-DexamethasoneConjugate to Liver
Macrophages
The anti-rat CD163 monoclonal antibody designated “ED2” used in
the following studies of drug targeting to CD163 has been shown to
target only macrophages44 and to have a plasma half-life of a few
minutes, owing to fast uptake in macrophage-rich organs (particu-
larly the liver, which accounts for the majority of the uptake).27,45
Fluorescence microscopy of liver sections from rats that were on a
standard diet and were injected intravenously (i.v.) with the ED2-
dexamethasone conjugate accordingly demonstrated speciﬁc vesicu-
lar uptake of this anti-CD163-dexamethasone conjugate in single
cells with a Kupffer cell-like shape and distribution (Figures 2C
and S2), whereas only weak non-speciﬁc staining was observed in
rats injected with the non-immune IgG-dexamethasone conjugate
(Figure 2D).
Ex vivo staining of isolated Kupffer cells incubated with the anti-
CD163-dexamethasone conjugate for 30 min demonstrated vesicular
uptake (in accordance with receptor-mediated endocytosis) and, to a
large extent, co-location of the anti-CD163-antibody and dexameth-
asone after 30 min of incubation (Figures 3A–3C). In contrast, injec-
tion of IgG-dexamethasone conjugate did not lead to staining of iso-
lated Kupffer cells (Figures 3D–3F).
Table 1. Organ Weight, Histological Scoring, and Paraclinical Characteristics of Rats Fed the HFr Diet
Parameter STD (n = 4) 2 weeks HFr (n = 4) 2 weeks STD (n = 8) 12 weeks HFr (n = 8) 12 weeks
Body weight (g) 260.6 ± 8.2 257.8 ± 3.6 454.8 ± 10.0 483.2 ± 7.2*
Liver/body weight (g/100 g) 3.4 ± 0.06 3.5 ± 0.11 3.6 ± 0.05 4.6 ± 0.11**
Spleen/body weight (g/100 g) 0.22 ± 0.01 0.21 ± 0.01
Steatosis (0–3) 0 1.25 ± 0.25** 0 3.00 ± 0.13**
Inﬂammation (0–3) 0 0.75 ± 0.25* 0 2.13 ± 0.25**
Hepatocyte ballooning (0–2) 0 0 0 1.75 ± 0.14**
Fibrosis (0–8) 0 0 0 5.25 ± 0.65**
Pericellular (0–4) 0 2.25 ± 0.25**
Perivenular (0–4) 0 3.00 ± 0.40**
Glycogen deposition (0–4) 0.25 ± 0.16 2.75 ± 0.31**
ALT (U/L) 43.4 ± 5.6 43.4 ± 2.7 66.4 ± 10.4 83.9 ± 16.4
AST (U/L) 136.3 ± 3.0 211.6 ± 19.4** 117.3 ± 11.7 134.6 ± 31.9
ALP (mM) 243.5 ± 17.1 151.9 ± 9.2** 188.3 ± 15.3 133.8 ± 3.7*
Glucose (mM) 4.8 ± 0.5 6.3 ± 0.5* 5.0 ± 0.2 8.5 ± 0.8**
Cholesterol (mM) 2.4 ± 0.1 2.4 ± 0.1 2.0 ± 0.2 2.6 ± 0.1*
HDL (mM) 1.4 ± 0.1 1.2 ± 0.1
Triglyceride (mM) 1.3 ± 0.1 1.0 ± 0.1* 1.5 ± 0.6 3.7 ± 0.5**
Creatinine (mM) 23.0 ± 1.5 17.5 ± 0.9*
Phosphate(mM) 1.6 ± 0.1 2.1 ± 0.1*
TNF-a (pg/mL) <ND 20.6 ± 9.4** 0.2 ± 0.05 11.0 ± 1.2**
IL-1b (pg/mL) <ND 9.4 ± 4.6 0.2 ± 0.03 11.5 ± 1.9**
Values are means ± SEM. Signiﬁcant differences between the control groups on the STD diet and the HFr diet after 2 and 12 weeks are indicated by *p < 0.05 and **p < 0.01,
respectively.
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Effect on HFr Diet-Induced Liver Changes by Targeting a
Low-Dose GC to CD163-Positive Macrophages
The treatment efﬁcacy of CD163-targeted low-dose dexamethasone
was subsequently studied in rats during early NASH disease progres-
sion (5 weeks on the HFr diet). Upon 2 weeks on the HFr diet, 32 rats
were randomized into four treatment groups (n = 8), maintained on
the HFr diet, and treated the following 3 weeks with i.v. injections
(three times per week) of vehicle, non-conjugated dexamethasone
(0.02 mg/kg), anti-CD163-dexamethasone conjugate (0.02 mg dexa-
methasone/kg), or control IgG-dexamethasone conjugate (0.02 mg
dexamethasone/kg). The treatment groups and doses used in the pre-
sent study were chosen on the basis of a short endotoxin-induced
inﬂammation experiment in rats (Table S2) with serum TNF-a as
the readout, as previously described.27 The dose response showed
the maximal effect of a single preventive injection of the anti-
CD163-dexamethasone conjugate at a dose of 0.02 mg dexametha-
sone/kg. No effect of the same dose of dexamethasone in a free
form or conjugated to an irrelevant IgG was seen, nor was there
any effect of free anti-CD163 IgG (Table S2) in accordance with
fast removal of the antibody by CD163.27,45
Three days after the last injection on day 36, the experiment was
terminated and the liver status of the rats was evaluated. The group
treated with the anti-CD163-dexamethasone conjugate showed
strongly reduced values of all analyzed histological liver lesion param-
eters (steatosis, inﬂammation, hepatocyte ballooning, ﬁbrosis, and
glycogen accumulation) contributing to NASH, relative to the pla-
cebo control; accordingly, the NAFLD activity score (NAS) (steatosis,
hepatocyte ballooning, and inﬂammation) was signiﬁcantly reduced,
whereas no effect was seen in rats treated with free dexamethasone
(Figure 4; Table 2). Some reduction in the overall score was seen in
Figure 2. CD163-Positive Liver Macrophages in Rats
on the Standard Diet versus the HFr Diet
(A and B) Anti-CD163 antibody staining of Kupffer cells/
infiltrating macrophages using immunohistochemistry of
fixed paraffin-embedded liver sections from rats fed the (A)
STD or (B) HFr diet for 2weeks.White scale bars represent
400 mm. (C and D) Fluorescence microscopic analysis of
formalin-fixed cryosections of rat liver 1 hr after i.v. injec-
tion of (C) the anti-CD163-dexamethasone conjugate and
(D) the control IgG-dexamethasone conjugate in rats on
the STD. Anti-mouse IgG-Alexa Fluor 488 (green) was
used for detection of the conjugates. Staining of the
CD163-dexamethasone conjugate is in accordance with
uptake in Kupffer cells (arrowheads). Scale bars represent
20 mm.
the group treated with the IgG-dexamethasone
conjugate, but steatosis and hepatocyte
ballooning contributing to the NAS was signiﬁ-
cantly exacerbated in the IgG-dexamethasone
group compared to the anti-CD163-dexa-
methasone group (p = 0.040 and p = 0.004,
respectively). Interestingly, Oil Red O staining
(Figure 5) showed that rats treated with free dexamethasone or
IgG-dexamethasone exhibited more pronounced macrovesicular
steatosis, which might be accounted for by a direct lipogenic effect
of dexamethasone taken up in hepatocytes. Furthermore, hepatic
ﬁbrosis, scored as the sum of pericellular and perivenular ﬁbrosis as
well as glycogen deposition, was signiﬁcantly reduced only in the
anti-CD163-dexamethasone group (Figure 4; Table 2).
Figures 6A and 6B illustrate the far higher efﬁcacy of the anti-
CD163-dexamethasone conjugate on liver weight and total NASH
score (representing the sum of all analyzed histological parameters
shown in Table 2), respectively, compared to similar doses of free
or IgG-coupled dexamethasone. This signiﬁcant treatment effect
on NASH progression was conﬁrmed by histological analyses in
an identical treatment setup including eight rats in each treatment
group.
Activity levels of the liver enzymes alanine transaminase (ALT), AST,
and lactate dehydrogenase (LDH) were lower in all treatment groups,
but the effect on ALT and AST levels was more pronounced in the
conjugate treatment groups (Table 2). Levels of glucose, triglyceride,
and cholesterol were signiﬁcantly lower in the anti-CD163-dexa-
methasone group compared to the IgG-dexamethasone group
(Table 2). Serum cytokine TNF-a levels were signiﬁcantly lower in
the conjugate treatment groups compared to the vehicle group,
whereas IL-1b serum levels were signiﬁcantly lowered in all three
treatment groups (Table 2).
RNA proﬁling of selected liver genes of potential relevance to NASH
pathology are shown in Table S4, showing that hepatic genes were
signiﬁcantly up- or downregulated more than 1.4-fold, relative to
www.moleculartherapy.org
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the vehicle-treated group. Treatment with dexamethasone (free or
conjugated) counter-regulated to some extent genes that were up-
or downregulated by the HFr diet, but only modest differences were
generally seen in the expression patterns of these genes, which are
active mainly in hepatocytes. However, of note, the genes involved
in mitochondrial b-oxidation were collectively upregulated only in
the anti-CD163-dexamethasone group. Also, the interferon-g gene
(Ifng), which has counteracting immunoregulatory properties,46,47
showed a marked upregulation in the anti-CD163-dexamethasone
group.
Systemic Effects of the Anti-CD163-Dexamethasone Conjugate
No behavioral changes were observed in the treatment groups.
Thymus weight, which is a common measure in rats for the systemic
effect of dexamethasone owing to a strong apoptosis-inducing effect
on lymphocytes, was signiﬁcantly lower in the free dexamethasone
group compared to vehicle, whereas no effect on thymus size was
seen in the conjugate groups (Table 2).
DISCUSSION
The present rat data show a strong positive effect of speciﬁc dexa-
methasone targeting to the M2 macrophage receptor CD163 in an
inﬂammatory model, where fructose induces rapidly progressing
steatosis followed by inﬂammation, hepatocyte ballooning, and
ﬁbrosis mimicking human NASH. Targeting Kupffer cells with low-
dose anti-CD163 conjugated dexamethasone substantially reduced
all histological parameters deﬁning NASH. Furthermore, the fruc-
tose-induced increase in liver weight, as well as the development of
pericellular and perivenular ﬁbrosis, was prevented and blood param-
eters of liver inﬂammation (ALT, AST, triglyceride, TNF-a, and IL-
1b) were also reduced. No or little effect on fructose-induced
NASH was seen with a similar dose of free dexamethasone. These
ﬁndings conﬁrm the pivotal role of macrophages in driving the liver
inﬂammation induced by fructose, keeping in mind that the activa-
tion of Kupffer cells and macrophage accumulation is a second line
of the pathogenesis. Any therapeutic effect of macrophage-directed
activity on hepatocytes may only occur indirectly via signaling by
Figure 3. Targeting of Anti-CD163-Dexamethasone to Rat Kupffer Cells
Confocal fluorescence microscopy analysis of liver cell suspensions after 30 min of incubation with (A–C) the anti-CD163-dexamethasone conjugate or (D–F) the IgG-
dexamethasone conjugate. (A and D) Anti-mouse IgG-Alexa Fluor 488 (green) staining of CD163 antibody. (B and E) Anti-rabbit Alexa Fluor 647 (red) staining of dexa-
methasone. (C) shows the overlay of (A) and (B) and (F) shows the overlay of (D) and (E), with DAPI (light blue) nuclei staining showing co-location of anti-CD163 and
dexamethasone. Scale bars represent 20 mm.
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macrophages, and this type of therapy may not abolish the primary
pathologic mechanisms initiating disease. This is also in accordance
with the present data showing that the main effect of the CD163-
directed therapy was on the secondary liver changes, whereas less
reduction of the direct fructose-induced hepatocyte changes such as
steatosis was seen.
Targeting GCs to CD163-positive macrophages has two major ad-
vantages. First, it decreases the effective anti-inﬂammatory dose
response approximately 50-fold, as estimated by measuring the cyto-
kine response in rats and pigs after endotoxin injections.27,29 Second,
it reduces off-targeting, which is essential in the liver because of the
strong diabetic effects of GCs in hepatocytes. In fact, the present
study shows that rats receiving low-dose dexamethasone in non-con-
jugated form actually developed increased macrovesicular steatosis
compared to the non-treated rats. Off-targeting effects in extrahe-
patic tissues are also a serious therapeutic problem with GCs. In
this study, the systemic effect was analyzed by weighing the thymus,
which is extremely sensitive to GC-induced apoptosis of its lympho-
cyte population. Reduced thymus weight in rats treated with free
dexamethasone is in line with previous data showing side effects of
equal and higher concentrations of free dexamethasone in rats.27
For comparison, dexamethasone is administered at doses of
1–10 mg per day in the clinic; even without correction by allometric
scaling, this dose is substantially higher than the dose used in rats
in the present study (0.02 mg dexamethasone/kg, three times per
week).
The molecular mechanisms of the NASH-attenuating effect by anti-
CD163-dexa treatment may bemultiple and need further exploration.
Figure 4. Anti-CD163-Dexamethasone Treatment Strongly Reduces Development of Steatohepatitis and Fibrosis in Rats on the HFr Diet
Treatment effects of free dexamethasone, anti-CD163-dexamethasone, and IgG-dexamethasone conjugates. The left panel represents H&E staining showing fat de-
positions, inflammation, and hepatocyte ballooning. The right panel represents Masson’s trichrome-stained sections showing hepatic regions with fibrosis (blue staining
represents collagen deposition). Magnification, 20. Scale bars represent 200 mm.
Table 2. Organ Weight, Histological Scoring, and Paraclinical Values in Rats Treated with Vehicle, Free Dexamethasone, Anti-CD163-Dexamethasone, and
IgG-Dexamethasone
Parameter Vehicle Dexa Anti-CD163-Dexa IgG-Dexa
Body weight (g) 314.5 ± 3.7 298.1 ± 5.2* 300.7 ± 3.9* 312.1 ± 5.5
Liver/body weight (g/100 g) 5.3 ± 0.10 5.2 ± 0.20 4.8 ± 0.04** 4.9 ± 0.20
Spleen/body weight (g/100 g) 0.22 ± 0.01 0.21 ± 0.01 0.22 ± 0.01 0.25 ± 0.01*
Thymus/body weight (g/100 g) 0.17 ± 0.01 0.12 ± 0.01* 0.15 ± 0.01 0.17 ± 0.01
Steatosis (0–3) 2.88 ± 0.13 2.50 ± 0.19 1.62 ± 0.18** 2.12 ± 0.12**
Inﬂammation (0–3) 2.12 ± 0.12 1.69 ± 0.25 1.00 ± 0.19** 1.38 ± 0.12**
Hepatocyte ballooning (0–2) 1.67 ± 0.13 1.38 ± 0.10 0.71 ± 0.10** 1.21 ± 0.11*
NAS score (0–8) 6.67 ± 0.28 5.56 ± 0.41 3.33 ± 0.03** 4.71 ± 0.31**
Fibrosis (0–8) 3.75 ± 0.45 3.75 ± 0.50 1.75 ± 0.25** 2.81 ± 0.29
Pericellular (0–4) 1.70 ± 0.34 1.88 ± 0.27 0.75 ± 0.25* 1.19 ± 0.13
Perivenular (0–4) 2.00 ± 0.27 1.88 ± 0.64 1.00 ± 0.19** 1.63 ± 0.18
Glycogen deposition (0–4) 2.19 ± 0.19 1.69 ± 0.25 1.06 ± 0.18** 1.75 ± 0.27
ALT (U/L) 334.1 ± 33.1 192.5 ± 16.5** 158.6 ± 13.7** 128.3 ± 8.5**
AST (U/L) 119.9 ± 19.9 101.4 ± 16.1 64.3 ± 7.6* 68.6 ± 5.3*
LDH (U/L) 2,414 ± 187.7 1,351 ± 102.8** 1,370 ± 75.7** 1,159 ± 124.5**
ALP (mM) 183.5 ± 7.1 198.6 ± 9.0 169.4 ± 6.8 166.6 ± 5.8
Glucose (mM) 9.1 ± 0.8 10.1 ± 0.8 11.5 ± 0.9 13.4 ± 1.3**
Cholesterol (mM) 1.8 ± 0.1 2.1 ± 0.1* 2.1 ± 0.1* 2.8 ± 0.2**
HDL (mM) 0.8 ± 0.1 1.24 ± 0.1** 1.3 ± 0.1** 1.3 ± 0.2
Triglyceride (mM) 3.9 ± 0.3 3.0 ± 0.2* 2.5 ± 0.2** 4.3 ± 1.0
Carbamide (mM) 9.3 ± 0.6 9.1 ± 0.5 6.7 ± 0.4** 7.7 ± 0.6*
Creatinine (mM) 19.2 ± 0.7 17.9 ± 1.5 16.0 ± 0.7* 15.1 ± 0.8**
TNF-a (pg/mL) 7.9 ± 1.1 6.1 ± 0.8 4.6 ± 0.6* 3.6 ± 0.6**
IL-1b (pg/mL) 253.0 ± 71.8 90.1 ± 27.0* 90.1 ± 37.1* 76.3 ± 20.8*
Values are means ± SEM (n = 8 per group). Signiﬁcant differences between the vehicle group and the dexa, anti-CD163-dexa, and IgG-dexa groups are indicated by *p < 0.05 and
**p < 0.01, respectively. dexa, dexamethasone.
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Previous data have shown that anti-CD163-dexa therapy strongly re-
duces the acute pro-inﬂammatory macrophage cytokine storm
(TNF-a in particular) induced by LPS27 that is suggested to play
role in NASH development.47 However, anti-TNF-a therapy has
not proved effective in treating NASH in humans,25 suggesting that
other factors are important in disease progression. This is also indi-
cated from results of the present study, where the increase in fruc-
tose-induced TNF-a measured at the termination of the study was
only partially reduced by anti-C163-dexa, and the effect was not
different from that of Ig-CD163-dexa. The transcription level of
INF-g in the anti-C163-dexa-treated animals was also surprising
because INF-g is normally regarded as a pro-inﬂammatory cytokine.
However, IFN-g has several immunoregulatory properties. IFN-g has
also been shown to speciﬁcally inhibit extracellular matrix synthesis,
which leads to deposition of scar or ﬁbrous tissue.48 Further, in vitro
studies of the effect of IFN-g on hepatic stellate cells, which are the
most important ﬁbrogenic cells in the liver, demonstrated that this
cytokine inhibits multiple aspects of stellate cell activation.49 Clinical
studies with IFN-g have demonstrated reduction of ﬁbrosis as well as
histological reversal of cirrhosis.46,50 Suppression of collagen1a1
(Col1a1) gene expression seems to be an important component in
this clinical effect of IFN-g.51 In line with these ﬁndings, there was
a trend that expression of Col1a1 was speciﬁcally decreased by the
anti-CD163-dexamethasone conjugate (1.6-fold downregulation,
p = 0.07, data not shown).
Figure 5. Hepatic Lipid Accumulation Visualized by
Red Oil O Staining
Red oil O staining of frozen liver sections counterstained
with hematoxylin showing red-colored micro- and mac-
rovesicular fatty droplets in areas of steatosis. The top
panel in (A) shows stainings of the liver of a rat on the STD
and at 12 weeks on the HFr diet, for comparison with the
four treatment groups in (B). Magnification, 63. Scale
bars represent 60 mm.
The Kupffer cell population is the major body
macrophage pool, which, in NASH, is further
supplemented with inﬁltrating CD163 macro-
phages (Figure 2). Accordingly, the majority
of injected anti-CD163 antibody is taken up
in the liver.45 A minor, but still a substantial,
fraction of injected anti-CD163-dexamethasone
may target other tissue macrophages though.
How this uptake impacts on NASH is
unknown, but along this line macrophages in
the adipose tissue are particular interesting
because the macrophage M1/M2 balance
inﬂuences on the lipid metabolism in the adi-
pose tissue and on triglyceride release to
plasma.52 Our data on liver did not indicate a
major change in the M1/M2 balance but it is
possible that the targeting of dexamethasone
to CD163-positive M2 macrophages in the adi-
pose tissue has an indirect regulating effect on altered lipid meta-
bolism in this tissue.
In the liver, several parameters indicated changes in the lipid meta-
bolism. For instance, the transcription of the three genes Acadl,
Cpt1a, and Fabp1 signiﬁcantly downregulated in the fructose-induced
NASH model, were collectively upregulated in the group treated with
anti-CD163-dexamethasone (Table S4). The encoded proteins are
highly involved in transport and mitochondrial b-oxidation of fatty
acids.53 Mitochondrial dysfunction caused by impaired b-oxidation
may lead to increased production of reactive oxygen species (ROS)
that may stimulate pro-inﬂammatory processes and contribute to in-
sulin resistance and metabolic abnormalities.53 Fatty acid oxidation
has been shown to attenuate inﬂammatory and endoplasmic reticu-
lum stress responses in human macrophages.54,55 Thus, the anti-
inﬂammatory potency and NASH-protective effect of the anti-
CD163-dexamethasone conjugate in rats on HFr diet might to
some extent relate to increased b-oxidation of fatty acids originating
from the conversion of fructose to triglycerides.
Although it was signiﬁcantly less effective than anti-CD163 dexa-
methasone, the IgG-dexamethasone conjugate also had some
reducing effect on NASH progression. The IgG-dexamethasone con-
jugate was shown to distribute differently in the liver and showed no
binding or uptake in isolated Kupffer cells. Due to the long circulation
www.moleculartherapy.org
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time of IgG, dexamethasone bound to non-immune IgG is likely to be
released in plasma, and perhaps it also to some extent targets Fc re-
ceptors on monocytic cells and other immune cells. However,
increased levels of serum TG and glucose compared to the vehicle
group indicate metabolic side effects of this non-CD163-targeted
conjugate. In line with these observations, RNA proﬁling showed
signiﬁcant upregulation of genes involved in fatty acid metabolism
and glucose uptake and transport in rats treated with IgG-
dexamethasone.
Targeting of dexamethasone to macrophages has also been investi-
gated by others56 using macrophage-targeting mannosylated albumin
with linked dexamethasone in a rat model of liver ﬁbrosis induced by
bile duct ligation. In line with our data, a decreased TNF-a response
and reactive oxygen species generation was seen, indicating less in-
ﬂammatory response. However, in stark contrast with our data, no
attenuation of ﬁbrosis was observed in that model. The model based
on bile intoxication might stimulate the ﬁbrosis-stimulating stellate
cells,57 which could be one reason for this difference. Furthermore,
the mannose receptor used for targeting is also expressed in endothe-
lial cells.58
In conclusion, selective anti-CD163-dexamethasone targeting of
Kupffer cells with a low-dose dexamethasone conjugate prevented
development of fructose-induced steatohepatitis in rats without
apparent serious systemic side effects. The data therefore point to
the CD163-positive macrophage population as a potential therapeutic
target to prevent progression of further liver damage in patients with
NASH with increased caloric intake, although such medical therapy
may not substitute dietary interventions. Furthermore, the macro-
phage-targeting principle with GCs or other anti-inﬂammatory drugs
might also be relevant for other inﬂammatory diseases, including
other liver diseases such as acute alcoholic hepatitis, which shares pa-
thology with NASH and has a several-fold accumulation of CD163-
positive macrophages in the liver.59,60 This disease has high mortality
and there is an imminent need for new targeted approaches.26
Figure 6. Liver Weight and Total NASH Score in
Treatment Groups of Rats with HFr-Induced NASH
(A) Treatment effect on liver weight in different treatment
groups (n = 8) of rats on the HFr diet. (B) Treatment effects
on total NASH score, defined as the sum of steatosis
(0–3), inflammation (0–3), hepatocyte ballooning (0–2),
fibrosis (0–8), and glycogen deposition (0–4). Lines
represent means ± SEM.
Dexamethasone was the GC chosen in the pre-
sent anti-CD163-antibody conjugate. Dexa-
methasone is a widely used high-potency GC
with no or low mineralocorticoid activity. Selec-
tive macrophage targeting of GCsmay, to a large
extent, circumvent the problem of systemic site
effects, mainly because of a much lower effective
dose of GCs. As an alternative approach to
develop safer GCs, a range of synthetic GCs with an apparent more se-
lective action on the GC receptor have been developed by others with
the aim to promote a stronger anti-inﬂammatory proﬁle.61 So far, such
new GC compounds have not proved successful in clinical studies,
perhaps (most likely) because activation of the glucocorticoid receptor
inevitably leads to the pleiotropic effects of GCs. However, it seems
likely that further optimization of GC therapy may be achieved by
combining chemical GC development and targeting to macrophages.
MATERIALS AND METHODS
Conjugate Preparations
The IgG-dexamethasone conjugate was synthesized by conjugating
dexamethasone (on average, four drug molecules per IgG) to primary
amino groups of either the murine anti-rat CD163 antibody (ED2;
Bio-Rad AbD Serotec) or to murine IgG (Sigma-Aldrich) as described
previously using a hemisuccinate linker.27
Fluorescence Microscopy
Male Sprague-Dawley rats (Taconic) were injected (i.v.) with anti-
CD163-dexamethasone (0.02 mg/kg) (n = 2) or IgG-dexamethasone
(0.02 mg/kg) (n = 2). One hour after injections, the rats were anesthe-
tized and perfused with ice-cold PBS before the livers were trimmed
into small blocks and ﬁxed by immersion ﬁxation with 10% neutral
buffered formalin solution (Sigma-Aldrich) for 2 hr. The livers
were further ﬁxed for 24 hr in 1% neutral buffered formalin, inﬁl-
trated with 2.3 M sucrose for 30 min, and then frozen in liquid nitro-
gen. One-micrometer cryosections for light microscopy (LM) were
obtained with a Leica EM FC6 cryo-ultramicrotome (Leica Microsys-
tems). For immunoﬂuorescence, the sections were preincubated in
PBS containing 0.02 M glycine and 0.5% bovine serum albumin fol-
lowed by incubation for 1 hr with goat anti-mouse IgG-Alexa Fluor
488 antibody (Abcam) for detection of the anti-CD163 antibody
and the control IgG. The stained sections were mounted with hydro-
philic mounting media containing an anti-fading reagent (DAKO)
and were examined by a Leica DMR microscope equipped with a
Leica DFC320 camera (Leica Microsystems).
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Further characterization of hepatic binding of the anti-CD163-dexa-
methasone conjugate was performed ex vivo by analysis of liver cell
suspensions. Small pieces of rat liver were digested using collagenase
VI (2 mg/g tissue; Sigma-Aldrich) at 37C for 30 min in Hank’s
balanced salt solution with calcium and magnesium chloride (Life
Technologies) and 2% BSA before they were ﬁltered through a cell
strainer and washed by centrifugation. The cell suspensions were
seeded in DMEM supplemented with 10% FBS in chamber slides
for 2 hr before gentle washing of the attached liver cells and further
incubation overnight. The cells were rinsed and incubated with either
the anti-CD163-dexamethasone or murine IgG-dexamethasone con-
jugate for 30 min. Dexamethasone was detected with a rabbit anti-
dexamethasone antibody (Abcam). A goat anti-rabbit Alexa Fluor
647 antibody (Abcam) and a goat anti-mouse IgG-Alexa Fluor 488
antibody (Abcam) were used as secondary antibodies for staining of
the conjugates. After ﬁxation of the cells, the chamber slides were
covered with mounting medium containing DAPI (Life Technolo-
gies) before laser confocal ﬂuorescence microscopy for visualization
of stained cells using a Zeiss LSM-710 confocal microscope system
(Carl Zeiss MicroImaging).
Rat Model and Dexamethasone Treatment
The experimental protocol was approved by the Danish Experi-
mental Animal Inspectorate (permission no. 2012-15-2934-00250).
Male Sprague-Dawley rats (120–140 g) were purchased from
Taconic. The animals were maintained under controlled tempera-
ture (20 ± 2C) and light (lights on 08:00–20:00 hr) and fed a
standard diet (Altromin) for 7 days before they were randomly
separated into diet or treatment groups. All rats had free access to
the respective diet and water during the experimental periods.
High fructose (70% fructose, 10% fat, and 20% protein) was pur-
chased from Research Diet.
In the initial time study to validate the model, the control group was
on the STD diet, while the HFr group received the high-fructose diet
speciﬁed above. Once a week for 12 weeks, four animals from the
HFr group were randomly selected for analysis of biochemical blood
parameters, liver histology, and RNA proﬁling. The animals were
fasted for 20 hr before termination. The ﬁnal group fed the HFr
diet was analyzed after 12 weeks (n = 8) and the control group
on the STD diet was analyzed after 2 weeks (n = 4) and 12 weeks
(n = 8). At termination, the rats were anesthetized with isoﬂurane
and the abdomen was opened. Following blood collection from
the left ventricle, the rats were perfused with ice-cold PBS before
dissection of small tissue pieces from the left lobe of the liver for
RNA preparation. Subsequently, the rats were perfused with 10%
neutral buffered formalin and organs were dissected and further
ﬁxed in 10% neutral buffered formalin for 24 hr before the determi-
nation of organ weights and the isolation of liver portions from the
left lobe.
In the treatment experiment that was performed twice, the rats
were fed the HFr diet for 2 weeks before being randomly divided
into four treatment groups (n = 8) and continued on the HFr diet.
The rats were injected (i.v.) three times per week for 3 weeks with
vehicle (PBS), dexamethasone-phosphate (0.02 mg/kg; Sigma), anti-
CD163-dexamethasone (0.02 mg/kg), or mouse IgG-dexamethasone
(0.02 mg/kg). Body weight and the amount of food and water intake
were determined three times a week. We found no signiﬁcant differ-
ences between consumption (weight) of food among the groups
(Table S3). The experiment was terminated 3 days after the ninth in-
jection, as described above.
Liver Histology and Immunohistochemistry
Histological assessment of the liver conditions was analyzed using
H&E, Masson’s trichrome, and periodic acid-Schiff stains of 3-mm
formalin-ﬁxed parafﬁn-embedded sections. The disease severity was
blindly evaluated according to the NAFLD scoring system.62 The
NAS, ranging from 0 to 8, was determined from the degree of steatosis
(0–3), hepatocyte ballooning (0–2), and lobular inﬂammation (0–3).
According to the NASH Clinical Research Network, a NAS of R5
corresponds to a diagnosis of deﬁnitive NASH. Fibrosis severity
was scored 0–8 and deﬁned by the sum of pericellular (0–4) and peri-
venular (0–4) ﬁbrosis scores (modiﬁed from Kleiner et al.62).
Glycogen deposition was scored from 0 to 4. Parafﬁn-embedded liver
tissue sections (3 mm) were analyzed by immunochemistry using a
mouse monoclonal anti-rat CD163 antibody (ED2; Bio-Rad AbD
Serotec) for detection of CD163 and visualized by peroxidase conju-
gated secondary antibody. Lipid and fat accumulation was analyzed
by Oil Red O staining of cryosections from frozen liver tissue. Quan-
titative measurements of staining were determined using ImageJ soft-
ware (NIH).
Measurement of Paraclinical Parameters
Blood samples were processed to serum and stored at 80C. A
Roche Hitachi Cobas 6000 (Roche Diagnostics) analyzer was
used to measure serum activity of ALT, AST, LDH, and alkaline
phosphatase (ALP), as well as concentrations of glucose, triglyceride,
total cholesterol, and high-density lipoprotein (HDL) cholesterol.
Serum levels of IL-1b and TNF-a were determined using commercial
ELISAs (Life Technologies) according to the manufacturer’s
recommendations.
Statistical Analyses
All data variables were tested for normal distribution. Normally
distributed variables are presented as means ± SEM. Multiple rat
groups were analyzed and compared for treatment effects using
two-way ANOVA. For comparison of the two groups, normally
distributed data were tested with the Student’s t test. Nonparametric
data were tested using the Kruskal-Wallis test, followed by the Wil-
coxon Mann-Whitney rank sum test. p values < 0.05 were considered
signiﬁcant. All statistical analyses were performed using GraphPad
Prism software (version 6.0 for Windows).
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